Liberum Capital assumed coverage on shares of Sensyne Health (LON:SENS) in a research report sent to investors on Thursday morning, ThisIsMoney.Co.Uk reports. The brokerage issued a buy rating and a GBX 260 ($3.40) price objective on the stock.
Separately, Peel Hunt reissued a buy rating on shares of Sensyne Health in a research report on Friday, October 4th.
Shares of LON SENS traded up GBX 12.50 ($0.16) during midday trading on Thursday, hitting GBX 128.50 ($1.68). 81,801 shares of the company’s stock were exchanged. The company has a debt-to-equity ratio of 1.60, a current ratio of 13.29 and a quick ratio of 13.22. Sensyne Health has a twelve month low of GBX 98 ($1.28) and a twelve month high of GBX 204.92 ($2.68). The company has a market cap of $165.22 million and a PE ratio of 7.06. The firm’s fifty day simple moving average is GBX 125.82 and its 200-day simple moving average is GBX 148.07.
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts.
Featured Story: Margin
Receive News & Ratings for Sensyne Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensyne Health and related companies with MarketBeat.com's FREE daily email newsletter.